VRCA Verrica Pharmaceuticals (VRCA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001660334
Cluster · 4 insidersC-suite buying · 4
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
15
13F, latest reported quarter
What the filings say about VRCA
Insiders, 180 days
+$210.9K net bought
4 buyers
Verrica Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Verrica Pharmaceuticals Inc. insiders bought a net $210.9K of stock across 69 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Aug 17, 2026.
- The trade is 23.6% of the 8,587 shares held after it.
- 3 other insiders bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CMO Rosenberg Noah L. bought about $10.0K of VRCA on Aug 18, 2026; 3 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 25, 2025.
- The trade is 20.9% of the 23,962 shares held after it.
- 3 other insiders bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Interim CFO Kirby John J. bought about $24.6K of VRCA on Aug 18, 2026; 3 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 25, 2025.
- The trade is 22.2% of the 27,000 shares held after it.
- 3 other insiders bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Zawitz David bought about $29.9K of VRCA on Aug 17, 2026; 3 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Aug 14, 2026.
- The trade is 2.4% of the 207,593 shares held after it.
- 3 other insiders bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President Rieger Jayson bought about $24.6K of VRCA on Aug 17, 2026; 3 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 25, 2025.
- The trade is 64.1% of the 6,557 shares held after it.
- 3 other insiders bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CMO Rosenberg Noah L. bought about $20.6K of VRCA on Aug 17, 2026; 3 other insiders bought within 30 days and 15 funds added in the latest 13F quarter.69 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$210.9K over 180 days
+$210.9K over 90 days
more than 81% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
15 funds bought in last quarter
below 73% of Pharma & Biotech
Revenue
+370.2% year over year
more than 92% of Pharma & Biotech
Margin
-50.3% net margin
more than 50% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
1.6% of the float short (float per yahoo 2026-10-27) · 3.8 days to cover · settled 2026-10-15
below 72% of Pharma & Biotech
The situation: each line is one rule over one dataset
4 insiders independently bought a net $210.9K while the stock fell 47% over six months, with no planned sales queued.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch VRCA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-12.2%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns VRCA: institutional holders (13F)
13F holdings, latest reported quarter
923,910 sh
$5.7M
783,923 sh
$4.8M
707,338 sh
$4.3M
471,559 sh
$2.9M
426,304 sh
$2.6M
Congress trades in VRCA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
VRCA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
VRCA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$205.8K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$13.4K position · as of 2026-06-30
0.0%
JNL/DFA U.S. Small Cap Fund
$12.1K position · as of 2026-06-30
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$829.0K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$356.0K position · as of 2026-05-31
0.0%
Avantis Total Equity Markets ETF
$2.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 4 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
4
Phase 2
1 active
3
Phase 3
3 active
What changed recently
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
2026-10-24 · Recruiting → Active Not Recruiting
Phase 3
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
2026-09-04 · Not Yet Recruiting → Recruiting
Phase 3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $210.9K bought by insiders over 180 days, 15 funds added last quarter. Each figure is a federal filing, dated the day it went public.
VRCA financials
Revenue growth
+370.2%
XBRL, annual
Net margin
-50.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$30.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM VRCA
| FY Dec 2025 | $35.6M |
| FY Dec 2024 | $7.6M |
| FY Dec 2023 | $5.1M |
| FY Dec 2022 | $9.0M |
| FY Dec 2021 | $12.0M |
| Jun 2026 | $5.9M |
| Mar 2026 | $5.0M |
| Dec 2025 | $5.1M |
| Sep 2025 | $14.3M |
| Jun 2025 | $12.7M |
| Mar 2025 | $3.4M |
| Dec 2024 | $344.0K |
| Sep 2024 | -$1.8M |
At each fiscal year end
Single quarter
Net margin, TTM
-102.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM VRCA
| FY Dec 2025 | -50.3% |
| FY Dec 2024 | -1,012% |
| FY Dec 2023 | -1,308% |
| FY Dec 2022 | -271.1% |
| FY Dec 2021 | -292.3% |
| Jun 2026 | -224.4% |
| Mar 2026 | -192.8% |
| Dec 2025 | -158.8% |
| Sep 2025 | -1.9% |
| Jun 2025 | +1.6% |
| Mar 2025 | -283.3% |
| Dec 2024 | -4,716% |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM VRCA
| FY Dec 2025 | n/a |
| FY Dec 2024 | -$61.0M |
| FY Dec 2023 | -$38.9M |
| FY Dec 2022 | -$19.0M |
| FY Dec 2021 | -$28.5M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$4.6M |
| Sep 2025 | $9.7M |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$16.1M |
| Sep 2024 | -$8.6M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
LongTermDebt as filed 2025-12-31 (6 months older than the period end) (includes the current portion); equity 2026-06-30
Debt to equity VRCA
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 2.17x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 2.33x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt VRCA
| FY Dec 2025 | n/a |
| FY Dec 2024 | -1.97x |
| FY Dec 2023 | -0.90x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -0.36x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -1.35x |
| Jun 2025 | -1.93x |
| Mar 2025 | -1.93x |
| Dec 2024 | -1.97x |
| Sep 2024 | -1.37x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity VRCA
| FY Dec 2025 | -240.5% |
| FY Dec 2024 | -1,547% |
| FY Dec 2023 | -224.1% |
| FY Dec 2022 | -67.4% |
| FY Dec 2021 | -107.0% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -240.5% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -1,547% |
| Sep 2024 | -2,060% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-83.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets VRCA
| FY Dec 2025 | -35.4% |
| FY Dec 2024 | -112.9% |
| FY Dec 2023 | -106.1% |
| FY Dec 2022 | -39.2% |
| FY Dec 2021 | -45.5% |
| Jun 2026 | -83.1% |
| Mar 2026 | -44.1% |
| Dec 2025 | -35.4% |
| Sep 2025 | -70.5% |
| Jun 2025 | -106.7% |
| Mar 2025 | -121.7% |
| Dec 2024 | -112.9% |
| Sep 2024 | -130.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital VRCA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-241.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed VRCA
| FY Dec 2025 | -43.7% |
| FY Dec 2024 | -147.0% |
| FY Dec 2023 | -124.3% |
| FY Dec 2022 | -56.5% |
| FY Dec 2021 | -89.9% |
| Jun 2026 | -241.9% |
| Mar 2026 | -77.9% |
| Dec 2025 | -43.7% |
| Sep 2025 | -137.3% |
| Jun 2025 | -185.1% |
| Mar 2025 | -185.7% |
| Dec 2024 | -147.0% |
| Sep 2024 | -159.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing VRCA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$48.4M
market value at close 2026-10-27 on 2026-07-31 shares, plus LongTermDebt as filed 2025-12-31 (6 months older than the period end) (includes the current portion), minus cash 2026-06-30
Enterprise value VRCA
| FY Dec 2025 | $48.7M |
| FY Dec 2024 | $303.9M |
| FY Dec 2023 | $3.1B |
| FY Dec 2022 | $1.1B |
| FY Dec 2021 | $2.6B |
| Jun 2026 | $93.9M |
| Mar 2026 | $70.3M |
| Dec 2025 | $48.7M |
| Sep 2025 | $41.2M |
| Jun 2025 | $499.4M |
| Mar 2025 | $403.9M |
| Dec 2024 | $303.9M |
| Sep 2024 | $639.0M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield VRCA
| FY Dec 2025 | n/a |
| FY Dec 2024 | -19.1% |
| FY Dec 2023 | -1.3% |
| FY Dec 2022 | -1.7% |
| FY Dec 2021 | -1.1% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -9.7% |
| Mar 2025 | -13.2% |
| Dec 2024 | -19.1% |
| Sep 2024 | -9.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing VRCA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $35.6M | $7.6M | $5.1M | $9.0M |
| Operating income | -$12.2M | -$65.9M | -$65.8M | -$21.3M |
| Net income | -$17.9M | -$76.6M | -$67.0M | -$24.5M |
| EPS (diluted) | -1.68 | -14.78 | -1.48 | -0.72 |
| Operating cash flow | -$17.6M | -$60.9M | -$38.6M | -$18.6M |
| Cash | $30.1M | $46.3M | $69.5M | $34.3M |
| Long-term debt | $0 | $31.0M | $42.9M | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
VRCA Stock Sonar score 6/7 axes
Find similar shapesCompareVRCA ranks highest on financial health (99th percentile) and growth (92nd), and lowest on profitability (18th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
VRCA filings, in plain words
Are Verrica Pharmaceuticals insiders buying or selling VRCA?
In the 180 days to 2026-10-28, Verrica Pharmaceuticals insiders were net buyers, a net $210.9K across purchases and sales reported on Form 4, by 4 buyers.
Read the full summary
In the 180 days to 2026-10-28, Verrica Pharmaceuticals insiders were net buyers of VRCA, a net $210.9K across purchases and sales reported on Form 4 by 4 buyers. 4 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
